Sorafenib (BAY 43-9006, Nexavar®), a Dual-Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature

Methods in Enzymology

Volumn 407, Issue , 2006, Pages 597-612

  Adnane, Lila ^a   Trail, Pamela A ^a   Taylor, Ian ^a   Wilhelm, Scott M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT;

EID: 33744513575     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(05)07047-3     Document Type: Review

References (34)

1. Ahmad T., and Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin. Cancer Res. 10 (2004) 6388S-6392S
2. Allen L.F., Sebolt-Leopold J., and Meyer M.B. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol. 30 (2003) 105-116
3. Arboleda M.J., Eberwein D., Hibner B., and Lyons J.F. Dominant negative mutants of mitogen-activated protein kinase pathway. Methods Enzymol. 332 (2001) 353-367
4. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., Einhorn E., Herlyn M., Minna J., Nicholson A., Roth J.A., Albelda S.M., Davies H., Cox C., Brignell G., Stephens P., Futreal P.A., Wooster R., Stratton M.R., and Weber B.L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62 (2002) 6997-7000
5. Cohen Y., Goldenberg-Cohen N., Parrella P., Chowers I., Merbs S.L., Pe'er J., and Sidransky D. Lack of BRAF mutation in primary uveal melanoma. Invest. Ophthalmol. Vis. Sci. 44 (2003) 2876-2878
6. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
7. Hotte S.J., and Hirte H.W. BAY 43-9006: Early clinical data in patients with advanced solid malignancies. Curr. Pharm. Des. 8 (2002) 2249-2253
8. Karasarides M., Chiloeches A., Hayward R., Niculescu-Duvaz D., Scanlon I., Friedlos F., Ogilvie L., Hedley D., Martin J., Marshall C.J., Springer C.J., and Marais R. B-aRAF is a therapeutic target in melanoma. Oncogene 23 (2004) 6292-6298
9. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., and Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63 (2003) 1454-1457
10. Kolch W. Ras/Raf signalling and emerging pharmacotherapeutic targets. Expert Opin. Pharmacother. 3 (2002) 709-718
11. Kolch W., Calder M., and Gilbert D. When kinases meet mathematics: The systems biology of MAPK signalling. FEBS Lett. 579 (2005) 1891-1895
12. Lowinger T.B., Riedl B., Dumas J., and Smith R.A. Design and discovery of small molecules targeting raf-1 kinase. Curr. Pharm. Des. 8 (2002) 2269-2278
13. Lyons J.F., Wilhelm S., Hibner B., and Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 8 (2001) 219-225
14. Marais R., and Marshall C.J. Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv. 27 (1996) 101-125
15. Minamoto T., Mai M., and Ronai Z. K-ras mutation: Early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers-a review. Cancer Detect. Prev. 24 (2000) 1-12
16. Monia B.P., Sasmor H., Johnston J.F., Freier S.M., Lesnik E.A., Muller M., Geiger T., Altmann K.H., Moser H., and Fabbro D. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA 93 (1996) 15481-15484
17. Mross K., Steinbild S., Baas F., Reil M., Buss P., Mersmann S., Voliotis D., Schwartz B., and Brendel E. Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. Int. J. Clin. Pharmacol. Ther. 41 (2003) 618-619
18. Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., Zhu Z., Giannini R., Salvatore G., Fusco A., Santoro M., Fagin J.A., and Nikiforov Y.E. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88 (2003) 5399-5404
19. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J., Salem G., Pohida T., Heenan P., Duray P., Kallioniemi O., Hayward N.K., Trent J.M., and Meltzer P.S. High frequency of BRAF mutations in nevi. Nat. Genet. 33 (2003) 19-20
20. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., and Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418 (2002) 934
21. Repasky G.A., Chenette E.J., and Der C.J. Renewing the conspiracy theory debate: Does Raf function alone to mediate Ras oncogenesis?. Trends Cell Biol. 14 (2004) 639-647
22. Richly H., Kupsch P., Passage K., Grubert M., Hilger R.A., Kredtke S., Voliotis D., Scheulen M.E., Seeber S., and Strumberg D. A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. Int. J. Clin. Pharmacol. Ther. 41 (2003) 620-621
23. Richly H., Kupsch P., Passage K., Grubert M., Hilger R.A., Voigtmann R., Schwartz B., Brendel E., Christensen O., Haase C.G., and Strumberg D. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int. J. Clin. Pharmacol. Ther. 42 (2004) 650-651
24. Sebolt-Leopold J.S., and Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4 (2004) 937-947
25. Sebolt-Leopold J.S., Van Becelaere K., Hook K., and Herrera R. Biomarker assays for phosphorylated MAP kinase. Their utility for measurement of MEK inhibition. Methods Mol. Med. 85 (2003) 31-38
26. Sharma A., Trivedi N.R., Zimmerman M.A., Tuveson D.A., Smith C.D., and Robertson G.P. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65 (2005) 2412-2421
27. Singer G., Oldt III R., Cohen Y., Wang B.G., Sidransky D., Kurman R.J., and Shih I.M. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 95 (2003) 484-486
28. Strumberg D., Richly H., Hilger R.A., Schleucher N., Korfee S., Tewes M., Faghih M., Brendel E., Voliotis D., Haase C.G., Schwartz B., Awada A., Voigtmann R., Scheulen M.E., and Seeber S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23 (2005) 965-972
29. Strumberg D., and Seeber S. Raf kinase inhibitors in oncology. Onkologie 28 (2005) 101-107
30. Strumberg D., Voliotis D., Moeller J.G., Hilger R.A., Richly H., Kredtke S., Beling C., Scheulen M.E., and Seeber S. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int. J. Clin. Pharmacol. Ther. 40 (2002) 580-581
31. Wilhelm S., and Chien D.S. BAY 43-9006: Preclinical data. Curr. Pharm. Des. 8 (2002) 2255-2257
32. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., and Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 (2004) 7099-7109
33. Yazdi A.S., Palmedo G., Flaig M.J., Puchta U., Reckwerth A., Rutten A., Mentzel T., Hugel H., Hantschke M., Schmid-Wendtner M.H., Kutzner H., and Sander C.A. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J. Invest. Dermatol. 121 (2003) 1160-1162
34. Yuen S.T., Davies H., Chan T.L., Ho J.W., Bignell G.R., Cox C., Stephens P., Edkins S., Tsui W.W., Chan A.S., Futreal P.A., Stratton M.R., Wooster R., and Leung S.Y. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 62 (2002) 6451-6455